Mod

• Ollama has launched a new proxy that allows Claude Desktop to run open-weights models, including Qwen, DeepSeek, and Kimi. • This update follows a failed initial integration attempt and is designed to bypass the model restrictions that caused the first version to stall. • The release comes shortly after Ollama secured a $65 million funding round in July to expand the accessibility of open models.

• Chinese AI firms, including DeepSeek, Moonshot AI, and Z.ai, are now providing consistent competition to leading AI models from the US and EU at the enterprise level. • The rise is driven by the technical capabilities and financial appeal of these models, challenging the previous dominance of Western AI ecosystems. • This shift is significant as it signals a narrowing gap in the global AI race, potentially altering the landscape of enterprise technology adoption.

• Youth-led protests, referred to as the "cockroach" movement, have emerged to challenge Prime Minister Narendra Modi's perceived political invincibility. • The unrest intensified around July 25, following actions by Education Minister Dharmendra Pradhan, highlighting growing systemic frustrations among India's youth. • These demonstrations are significant because they expose vulnerabilities and "cracks" in the BJP's highly organized political machine and Modi's strongman image.

• Moderna and Merck have reported positive results from a large Phase 3 clinical trial of a personalized mRNA-based cancer vaccine designed to treat melanoma. • Unlike traditional treatments, this therapy trains a patient's own immune system to recognize and destroy the specific cancer cells threatening them. • This breakthrough represents a major step forward in precision oncology, moving away from broad attacks on cancer cells toward highly targeted immunotherapy.

• Moderna and Merck are developing personalized cancer vaccines designed to train the immune system to target mutations specific to an individual's tumor. • The treatment represents a potential breakthrough in oncology by shifting toward highly tailored immunotherapy rather than one-size-fits-all approaches. • Clinical trial results for colon cancer are anticipated in 2027, with data for pancreatic cancer trials expected to follow by 2031.

• Merck and Moderna announced that their cancer vaccine, intismeran, successfully met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 trial. • The study focused on patients with completely resected stage IIB-IV melanoma, marking a significant milestone in testing whether Moderna's mRNA technology can be effectively applied to oncology. • This success is part of a broader strategy to treat cancer earlier in its progression, with Merck currently conducting over 30 registrational studies across various cancer types.

• Moderna and Merck announced that a personalized mRNA cancer vaccine successfully slowed the recurrence and spread of melanoma in a late-stage clinical trial. • The vaccine was administered in combination with Merck's immunotherapy drug, Keytruda, to enhance the body's immune response against the cancer. • This result is significant as it demonstrates the potential for mRNA technology to be adapted for oncology, moving beyond its success in COVID-19 vaccinations.